[Edaily Reporter Shin Ha-yeon ] BCWORLDPHARM Co., Ltd.(200780)announced on the 3rd that it has expanded its portfolio of oral disintegrating tablets (ODTs) for cardiovascular conditions by launching the hypertension treatment “Ambarodi Tablets” on the 1st of this month.

Ambarodi Tablets are orally disintegrating tablets containing amlodipine besylate, a calcium channel blocker (CCB), and were launched in two dosages: 5 mg and 10 mg.

BCWORLDPHARM Co., Ltd. has previously supplied “Telbar ODT Tablets,” containing telmisartan, and “Subar ODT Tablets,” containing rosuvastatin. The company explained that with the launch of Ambar ODT Tablets, it has expanded its series of oral disintegrating tablets for cardiovascular diseases to three products, thereby strengthening its product competitiveness.

The company expects that this will not only provide a variety of dosage form options for patients with hypertension who require long-term medication but also improve medication adherence for elderly patients, those with dysphagia, and patients taking multiple medications.

BCWORLDPHARM Co., Ltd. plans to develop additional oral disintegrating tablet pipelines, including an amlodipine combination product, while expanding its oral disintegrating tablet portfolio beyond cardiovascular diseases into various therapeutic areas based on its accumulated formulation technology and taste-masking technology.

A BCWORLDPHARM Co., Ltd. official stated, “This achievement is significant not only because it marks the launch of a new product but also because it demonstrates our company’s consistent R&D capabilities,” adding, “We hope the launch of Ambarodi Tablets will be recognized as a meaningful outcome that aligns with our company’s mission: ‘To wholeheartedly strive for a better future for patients.’”